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ABSTRACT
Background: Graft infections are severe complications of vascular surgery
that may result in amputation or mortality. Staphylococci are the most frequent
cause of vascular graft infections.
Objective: In this study we assessed the prophylactic efficacy of linezolid 
in comparison with vancomycin in preventing prosthetic vascular graft infec-
tion due to methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-
resistant Staphylococcus epidermidis (MRSE).
Methods: This randomized, controlled, experimental study using healthy
adult (aged >5 months) male Wistar rats was conducted in the research labora-
tory of the Pamukkale University, Denizli, Turkey. The study consisted of an
uncontaminated control group and 3 groups for both staphylococcal strains: a
contaminated group that did not receive any antibiotic prophylaxis; a contami-
nated group that received preoperative intraperitoneal (IP) prophylaxis with
vancomycin; and a contaminated group that received preoperative IP prophy-
laxis with linezolid. All rats received a vascular Dacron graft placed inside a sub-
cutaneous pocket created on the right side of the median line. Sterile saline
solution (1 mL), to which MRSA or MRSE at a concentration of 2  107 colony-
forming units per milliliter had been added, was inoculated onto the graft surface
using a tuberculin syringe to fill the pocket. The grafts were explanted 7 days
after implantation and assessed by quantitative culture.
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Results: Seventy rats (mean [SD] weight, 323.7 [17.9] g; mean [SD] age,
5.98 [0.64] months) were evenly divided between the 7 groups. Statistical
analysis of the quantitative graft culture suggested that both vancomycin
and linezolid were effective in significantly inhibiting bacterial growth when
compared with the untreated contaminated groups (all, P < 0.001). However,
a statistically significant difference was not observed between the bacteria
count in the vancomycin and linezolid prophylaxis groups. When a compari-
son was made between the bacterial growth in the contaminated control
groups, MRSA had significantly greater affinity to the Dacron prostheses than
MRSE (all, P < 0.001).
Conclusion: Our study found that linezolid was as effective as vancomycin
in suppressing colony counts in MRSA- or MRSE-infected vascular Dacron grafts
in rats. (Curr Ther Res Clin Exp. 2007;68:23–31) Copyright © 2007 Excerpta
Medica, Inc.
Key words: vascular graft infection, linezolid, vancomycin.
INTRODUCTION
Graft infections are severe complications of vascular surgery, and management
is difficult, time-consuming, costly, and can result in amputation or mortality.1–3
Consequently, every attempt should be made to prevent vascular graft infections.
Staphylococci, which are skin commensals, are known to be the most frequent
cause of vascular graft infections in humans.1,4
We previously reported that vancomycin and teicoplanin reduced graft infec-
tion in rats after challenge with methicillin-resistant Staphylococcus epidermidis
(MRSE).5,6 However, the increasing prevalence of methicillin-resistant staphylo-
cocci worldwide is an important concern because of the limited number of
antimicrobial agents that are effective against these organisms.7–9 Consequently,
novel therapeutic approaches are required.
Linezolid is a new synthetic antimicrobial agent that is highly active against
gram-positive organisms, including methicillin-resistant organisms.10,11 In a study
by Rybak et al,12 linezolid was comparable to vancomycin in preventing the
growth of gram-positive organisms.
Because the investigations of linezolid in vascular infections have been
limited and the evaluation of new drugs is essential, we decided to investi-
gate its prophylactic efficacy in preventing vascular graft infections and to
compare it with vancomycin, which is more familiar to physicians and which
we recently found to be a good prophylactic agent.5 An English language lit-
erature search of PubMed (1990–2006) was performed using the search terms
vascular graft infection, linezolid, and vancomycin.
The aim of our study was to test the prophylactic efficacy of linezolid in pre-
venting prosthetic vascular graft infection due to methicillin-resistant
Staphylococcus aureus (MRSA) and MRSE and to compare it with vancomycin,
which is more commonly used in vascular surgery than linezolid.
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MATERIALS AND METHODS
The study was approved by the Pamukkale University Animal Research Ethics
Committee (Denizli, Turkey). All animals received humane care in compliance
with the principles of laboratory animal care developed by the National Academy
of Sciences.13
Organisms and Susceptibility Testing
The MRSA and MRSE strains were isolated from a clinical specimen (graft
infection) submitted for routine bacteriologic investigation to the Pamukkale
University Department of Microbiology. The clinical isolates were identified by
Gram staining, catalase reaction, tube coagulation test, and API-Staph test
(bioMérieux, Lyon, France). Methicillin sensitivity was investigated using an
oxacillin disk diffusion test.14
Drugs
Linezolid (Pfizer, Halden, Norway) and vancomycin (Abbott, Saint-Remy sur
Avre, France) were diluted as described in previous studies.15,16 The doses of
vancomycin and linezolid (10 mg/kg) were based on dose regimens that had
been found to be effective in the prevention of vascular graft infections in
animal studies.15–17 The drug solutions were prepared on the day of assay. The
antimicrobial susceptibilities of the strains to linezolid and vancomycin were
determined using the Kirby-Bauer disk diffusion method, according to the pro-
cedure outlined by the Clinical and Laboratory Standards Institute,18 and the
strains were found to be susceptible to vancomycin and linezolid.
In Vivo Rat Model
In this randomized, controlled, experimental study, healthy adult (aged 
>5 months) male Wistar rats were equally and randomly assigned to 7 groups:
group I (uncontaminated control group: implanted graft, no contamination, no
antibiotic prophylaxis); group II (untreated control group: implanted graft, local
contamination with MRSA, no antibiotic prophylaxis); group III (implanted graft,
local contamination with MRSE, no antibiotic prophylaxis); group IV (implanted
graft, local contamination with MRSA, prophylaxis with preoperative intraperi-
toneal [IP] vancomycin 10 mg/kg); group V (implanted graft, local contamination
with MRSE, prophylaxis with preoperative IP vancomycin 10 mg/kg); group VI
(implanted graft, local contamination with MRSA, prophylaxis with preopera-
tive IP linezolid 10 mg/kg); and group VII (implanted graft, local contamination
with MRSE, prophylaxis with preoperative IP linezolid 10 mg/kg).
All rats were anesthetized with a 2:1 mixture of ketamine hydrochloride
100 mg/mL (Pfizer, Luleburgaz, Turkey):xylazine hydrochloride 20 mg/mL
(Bayer AG, Leverkusen, Germany) 0.75 mL/kg IM. The hair on each rat’s back
was shaved and the skin was disinfected with 10% povidone-iodine solution. A
1.5-cm incision was made to create a subcutaneous pocket on the right side of the
median line. Under sterile conditions, a 1-cm2 sterile, woven, gelatin-impregnated
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Dacron graft (Gelwave, Sulzer Vascutek Ltd., Inchinnan, United Kingdom) was im-
planted in the pocket. In addition, the effect of preoperative intraperitoneal van-
comycin (groups IV and V) and linezolid (groups VI and VII) administered 30 min-
utes before implantation at the standard dose of 10 mg/kg was assessed. The
pocket was closed using skin clips. Sterile saline solution (1 mL), to which MRSA 
or MRSE at a concentration of 2  107 colony-forming units (CFUs) per milliliter had
been added, was inoculated onto the graft surface using a tuberculin syringe to
fill the pocket. The animals were returned to their individual cages and checked
daily for progress in healing and signs of wound infection. During the entire study,
the animals were kept at the Animal Research Laboratory (Pamukkale University,
Denizli, Turkey) under veterinary supervision. The rats were kept at a room tem-
perature of 25°C ± 1.9°C and humidity of 52% ± 6%, and received a standard diet 
as well as water ad libitum. All grafts were explanted under sterile conditions 7 days
after implantation (Figure). All animals were euthanized following explantation.
Infection Assessment
The explanted grafts were placed in sterile tubes and washed in sterile saline
solution. They were then placed in tubes containing 10 mL of phosphate-
buffered saline solution and sonicated for 5 minutes to remove the adherent
bacteria from the grafts. Quantitation of viable bacteria was performed by cul-
Figure. Removal of an implanted Dacron vascular graft from an adult male Wistar rat.
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turing consecutive 10-fold dilutions (0.1 mL) of the bacterial suspension on
blood agar plates. All plates were incubated at 37°C for 48 hours and assessed
for the presence of the staphylococcal strains. The organisms were quantitated
by counting the number of CFUs per plate.18
Statistical Analysis
Quantitative culture results were presented as mean (SD). Differences among
the groups were assessed using 1-way analysis of variance, and multiple com-
parisons between the groups were performed with the Tukey post hoc honestly
significant difference test. Differences were considered statistically significant
when P < 0.05. Statistical analysis and animal randomization were performed
using SPSS version 11.0 (SPSS Inc., Chicago, Illinois).
RESULTS
Seventy rats (mean [SD] weight, 323.7 [17.9] g; mean [SD] age, 5.98 [0.64] months)
were equally divided among the 7 groups. Evidence of graft infection was present
in all rats included in the untreated control groups (groups II and III). In contrast,
none of the animals included in the uncontaminated control group (group I) had
anatomic or microbiological evidence of graft infection. All the groups that re-
ceived preoperative intraperitoneal antibiotic prophylaxis suggested evidence
of infection, although with reduced quantitative bacterial graft culture results in
comparison with the untreated control groups.
The results of the quantitative graft culture are summarized in the table.
Statistically significant differences were observed between the results of the
quantitative bacterial graft cultures when the data obtained from all prophylaxis-
treated groups (groups IV–VII) were compared with those obtained from the
untreated contaminated groups (all, P < 0.001). However, no statistically sig-
Table. Quantitative microbiologic results from in vivo experiments on methicillin-
resistant staphylococci in vascular grafts implanted in rats for 1 week.
Preoperative Quantitative Graft Culture,
Group Microorganism Intraperitoneal Drug Mean (SD), CFUs/mL
I – – 0*†
II MRSA – 2.6  107 (6.1  106)
III MRSE – 6.6  106 (2.6  106)*
IV MRSA Vancomycin 6.7  102 (3.7  102)*†
V MRSE Vancomycin 5.6  102 (3.8  102)*†
VI MRSA Linezolid 8.2  102 (4.5  102)*†
VII MRSE Linezolid 7.0  102 (5.6  102)*†
CFU = colony-forming unit; MRSA = methicillin-resistant Staphylococcus aureus; MRSE = methicillin-
resistant Staphylococcus epidermidis.
*P < 0.001 versus group II.
†P < 0.001 versus group III.
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nificant between-group differences were observed when the bacteria counts
were compared between the vancomycin and linezolid prophylaxis groups con-
taminated with MRSA and MRSE. In the contaminated control groups (groups II
and III), MRSA had greater affinity to Dacron prostheses than MRSE (P < 0.001).
However, no significant difference was found between the affinity of MRSA and
MRSE to Dacron grafts when all the contaminated groups were compared.
Finally, none of the study animals died or had clinical evidence of drug-related
adverse events (eg, signs of perigraft inflammation, anorexia, vomiting, diar-
rhea, or altered behavior).
DISCUSSION
In this prosthetic vascular graft infection study, prophylaxis with linezolid
(10 mg/kg) or vancomycin (10 mg/kg) was associated with significant decreases
in the quantitative bacterial graft cultures compared with those of the controls.
The prophylactic efficacy of linezolid in terms of bacteria counts was similar to
that of vancomycin.
Staphylococci are the most commonly isolated microorganisms in vascular
surgical procedures,19 and the emergence of resistant gram-positive bacteria is
of particular concern.20,21
Because of the existence of methicillin-resistant staphylococci, vancomycin has
been the drug of last resort in many cases. Studies have reported vancomycin-
resistant clinical isolates.22,23 These are warning signs that emphasize the need
for new prophylactic approaches with alternative antistaphylococcic compounds
in vascular surgery. Linezolid is the first licensed drug in the oxazolidinone
class of antibiotics. Consistent in vitro antimicrobial activity against methicillin-
resistant staphylococci is an important attribute of linezolid.24–26
In this study, we found that both vancomycin and linezolid, when used for
preventing vascular graft infection, resulted in significant inhibition of bacterial
growth. However, the question arises as to whether the antibiotics used in this
study can be recommended for clinical use. These antibiotics should be used as
prophylactic agents in surgical centers where active surveillance has suggested
that methicillin-resistant staphylococci are often the cause of device-related
infections.27–29 The unnecessary use of these antibiotics may result in selection
for resistant organisms that may be carried to other patients and produce more
serious infections.30 Infections due to glycopeptide-resistant gram-positive organ-
isms are difficult to treat, and there have been increased morbidity and mortali-
ty associated with these infections.31 As linezolid is a new antibiotic that does
not possess inherent cross-resistance to other antibiotic classes nor rapid in
vitro resistance,32,33 it may be included as a new prophylactic agent to delay the
emergence of resistant staphylococcal strains. Unfortunately, linezolid resis-
tance in S aureus has been reported.34,35
To prevent the emergence of resistant microorganisms, programs to educate
health care workers about infection-control precautions against S aureus with
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glycopeptide and linezolid resistance should be developed and infection-control
specialists should monitor compliance with these precautions. Additionally,
health care workers should be educated periodically about the indications for
glycopeptides and linezolid to reduce the overuse and misuse of these drugs.
In our model, the explanted grafts were sonicated to remove the adherent
bacteria. Therefore, we were able to obtain quantitative cultures of both the
bacteria included on the graft material and those grown on biofilm surrounding
the Dacron prostheses.
This experimental study has several limitations and caution regarding the
application of these results is needed. Our in vivo model used a direct method
of MRSA and MRSE colonization on the graft. Thus, the animal model in our
study is not directly comparable with graft implantation into a blood vessel.
Additionally, the antibiotics were administered intraperitoneally instead of
intravenously, and antibiotic binding to the Dacron grafts was not assessed.
These results should be compared with the findings in the clinical setting of
grafts implanted in the arteries of human patients. Our report suggests that the
use of linezolid as a prophylaxis for vascular graft infection is worthy of further
research, especially in humans.
CONCLUSION
In this experimental study, prophylactic use of linezolid was found to be effica-
cious in significantly reducing colony counts in MRSA- or MRSE-infected vascular
Dacron grafts in rats, and its prophylactic efficacy was comparable to that of an
established vancomycin regimen.
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